SK Bioscience joins $99m BDBV vaccine development project
Predicted impact: Low
Ebola vaccine project participation already reported; project worth about 99M dollars.
SK BioscienceSK바이오사이언스
302440 · KOSPI · ₩302440 · SK바이오사이언스
₩32,150▲ ₩400 (1.26%)End-of-day · Oct 28, 2026 · End-of-day prices.
SK Bioscience to Develop and Produce Ebola Vaccine with US Government Support
Predicted impact: Low
Ebola vaccine project joins ₩131B US-backed program, about 5% of revenue; already reported.
SK Bioscience Joins U.S.-Backed Ebola Project
Predicted impact: Low
Government-backed Ebola project worth ₩131B already reported in recent items.
SK Bioscience to Develop Ebola Vaccine with Overseas Partner for Bundibugyo Strain
Predicted impact: Medium
Partner development deal is about 20% of revenue, but already reported.
SK Bioscience works with global partners on Bundibugyo Ebola vaccine development and production
Predicted impact: Medium
₩131B project is about 20% of revenue, but the same news was already reported.
SK바이오사이언스, 미국정부 에볼라 백신 개발 프로젝트 참여
Predicted impact: Low
Ebola vaccine project participation already reported in item 3 from same company.
SK Bioscience Develops Ebola Vaccine for Bundibugyo with US Support, Joins ₩131B Project
Predicted impact: Low
Ebola vaccine development joining a ₩131B government-backed project; size vs revenue is small.
Inics Acquisition Boosts SK Bioscience's Flu and Ebola Vaccine Business [Stars IR]
Predicted impact: Low
Commentary on an earlier acquisition's benefits to vaccine business; no new deal size or figures given.
SK Bioscience introduces AI into flu vaccine production to help improve yields
Predicted impact: Low
AI adoption in vaccine production already reported; incremental yield benefit is vague and unquantified.
SK바이오사이언스, 백신 생산 현장에 AI 도입
Predicted impact: Low
AI adoption in vaccine production is a vague operational item with no size given.
Also known as: SK Bioscience / SK바이오사이언스 / 302440 / KRX:302440
Source: KRX statistical information